Ghassan Abou-Alfa, MD, MBA: With all this said, we come to ASCO [the American Society of Clinical Oncology annual meeting] this year and we hear about the ABC-06 trial. Martin, please talk about ABC-06.

Martin Gutierrez, MD: The ABC-06 trial is actually second-line FOLFOX [folinic acid/fluorouracil/oxaliplatin] chemotherapy versus a standard of care or best care therapy. Again, I think it started to show positive results on the study. If I recall correctly, the data, don’t quote me on it, was about 162 patients total. Most of those patients had a survival advantage on the FOLFOX regimen versus the best standard of care therapy regimen.

Ghassan Abou-Alfa, MD, MBA: I totally agree with you. This is probably a little bit early for us to look into ABC-06 because all of us heard it in abstract form and are waiting for the data. Of course, 1 of the questions that was brought up is what actually Dr Angela Lamarca MD, PhD, MSc at that time brought up about chemotherapy—GemCis [gemcitabine/cisplatin]-resistant, gemcitabine/cisplatin-intolerant, and other categories. We’re waiting for the manuscript to see a little bit more delineation in that. But interestingly, with this suggestion that there could be a second-line approach, and by the way, there has been no other study that was off, but there had been some retrospective looks. One of them was just published jointly by different institutions, being UCSF [University of California, San Francisco], Vanderbilt University, and Memorial Sloan Kettering Cancer Center, looking into the second-line therapy. Of course, there are different approaches, among which there is FOLFIRI [folinic acid/fluorouracil/irinotecan], and sometimes intrahepatic arterial pump if it’s available, and so forth.

Transcript Edited for Clarity